Vaxxinity Company Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated α-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy.
It also develops VXX-401, that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313, which is in Phase 1 clinical trial targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial.
It has a collaboration agreement with the University of Florida, University of Central Florida, and the University of Southampton.
The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Mei Hu |
Contact Details
Address: 505 Odyssey Way Merritt Island, Delaware 32953 United States | |
| Phone | 254 244 5739 |
| Website | vaxxinity.com |
Stock Details
| Ticker Symbol | VAXX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US92244V1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mei Mei Hu J.D. | Co-Founder, President, Chief Executive Officer and Director |
| Louis Garfield Reese IV | Co-Founder and Executive Chairman of the Board |
| Sumita Ray J.D. | Chief Legal, Compliance and Administrative Officer and Corporate Secretary |
| Jason Pesile CPA, M.B.A. | Chief Accounting Officer |
| Dr. Jean-Cosme Dodart Ph.D. | Chief Scientific Officer |
| Mark Joinnides MSE | Chief of Staff |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |